Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Other financing activities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Other financing activities for 8 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities fell 1893.74% year-over-year to -$3.0 million, compared with a TTM value of -$16865.0 through Dec 2025, up 92.53%, and an annual FY2025 reading of -$16865.0, down 107.47% over the prior year.
  • Other financing activities was -$3.0 million for Q4 2025 at Abvc Biopharma, down from $3.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $3.0 million in Q3 2025 and bottomed at -$3.0 million in Q4 2025.
  • Average Other financing activities over 5 years is -$120162.6, with a median of $10514.5 recorded in 2023.
  • The sharpest move saw Other financing activities surged 757.52% in 2024, then tumbled 1893.74% in 2025.
  • Year by year, Other financing activities stood at -$1.2 million in 2021, then skyrocketed by 79.66% to -$245665.0 in 2022, then skyrocketed by 106.51% to $16000.0 in 2023, then plummeted by 1055.64% to -$152902.0 in 2024, then crashed by 1893.74% to -$3.0 million in 2025.
  • Business Quant data shows Other financing activities for ABVC at -$3.0 million in Q4 2025, $3.0 million in Q3 2025, and $19681.0 in Q2 2025.